Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patientsShumin Yuan, Zibing Wang, Ling Peng et al.|Cancer Immunology Immunotherapy|2022Cited by 19
Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder CarcinomaYonghao Yang, Zibing Wang, Jun Li et al.|Frontiers in Oncology|2021Cited by 4
Effect of reducing the number of neoadjuvant chemoimmunotherapy cycles on clinical efficacy in locally advanced PD-L1 positive gastric cancer: A single center phase 2 study.Lingdi Zhao, Quanli Gao, Xiangbin Wan et al.|Journal of Clinical Oncology|2023Cited by 1
Neoadjuvant therapy using PD-1 inhibitor plus chemotherapy with different intervals between chemotherapy cycles for locally advanced gastric or gastroesophageal junction cancer: A randomized phase 2 study.Quanli Gao, Zhi Li, Lingdi Zhao et al.|Journal of Clinical Oncology|2024Cited by 0